Sign In
Buy LLY
$1,083.23
+18.39 (+1.73%)
At Close: Jun 03, 2026
Eli Lilly's Eczema Drug Shows Strong Skin Clearance In Phase 3 Pediatric Trial
08:43am, Monday, 16'th Mar 2026
Eli Lilly's Phase 3 results for Ebglyss in children with severe eczema, shows skin clearance and itch relief in trial patients.
In the Phase 3 ADorable-1 study, 63% of patients achieved meaningful skin improvement (EASI-75) and 44% achieved clear or almost clear skin (IGA 0,1) at Week 16 In key secondary endpoints, 39% of pati
3 Stocks That Could Be Next to Announce a Stock Split
10:05am, Sunday, 15'th Mar 2026
Stock splits are actions taken by corporations to make their shares nominally affordable for more retail investors. These usually occur after a period of significant growth and/or innovation.
Is Eli Lilly's Weight Loss Empire in Trouble?
06:30pm, Friday, 13'th Mar 2026
Several pharmaceutical companies have recently posted encouraging clinical data for their weight-loss candidates. However, most of these won't be approved soon, and Eli Lilly has strong programs of it
Invesco Rising Dividends Fund Q4 2025 Portfolio Activity
12:23pm, Friday, 13'th Mar 2026
Linde was purchased due to its essential and resilient business model, anchored by long-term contracts and leadership in industrial gases. We sold Oracle due to concerns about downside risk as its inv
Here's Why Eli Lilly (LLY) is a Strong Growth Stock
10:45am, Friday, 13'th Mar 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Eli Lilly Warns Tirzepatide-B12 Mix in Compounded Drugs May Pose Safety Risks
02:21pm, Thursday, 12'th Mar 2026
Eli Lilly (LLY) has raised new safety concerns around compounded versions of its weight-loss medicine Zepbound, warning that the drug's active ingredient, tirze
Using Obesity Drug? Eli Lilly Flags Unknown Impurity Found In Compounded Weight Loss Drugs With Vitamin B12
02:04pm, Thursday, 12'th Mar 2026
Eli Lilly and Co (NYSE: LLY) on Thursday issued a public warning about potential safety risks linked to compounded tirzepatide products that are mixed with vitamin B12.
Megatrends Still Matter: 3 Growth Stocks for the Next 10 Years
09:37am, Thursday, 12'th Mar 2026
A megatrend is a long-term shift that affects many aspects of society and shapes the future over many decades. The internet would be an example of a megatrend, and perhaps more specifically, the smart
Novo Nordisk stock slump hits value of controlling shareholder
08:12am, Thursday, 12'th Mar 2026
Novo Nordisk (NVO, Financials) has witnessed its share price plummet over the previous year, reducing the value of its largest shareholder's holdings.Novo Holdi
Is The Private Credit Party Over?
07:15am, Thursday, 12'th Mar 2026
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
Eli Lilly: The Weight-Loss Craze Isn't Over
06:54am, Thursday, 12'th Mar 2026
Eli Lilly is rated a strong buy with a $1,623 price target, driven by multiple near- and long-term catalysts. Orforglipron's Q2 launch and Medicare/Medicaid eligibility will expand LLY's addressable m
Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline
06:46am, Thursday, 12'th Mar 2026
British drugmaker AstraZeneca Plc (NYSE: AZN) has emerged as the leading contender to acquire French biotech Abivax SA (NASDAQ: ABVX), following the company's dramatic valuation surge after strong cli
India warns drugmakers against direct or surrogate weight-loss drug and obesity ads
03:26pm, Wednesday, 11'th Mar 2026
India's drug regulator has warned pharmaceutical companies against direct or indirect advertising of weight-loss medicines, including obesity awareness campaigns that could act as surrogate promoti
Forget Oral Wegovy: This Weight Loss Drug Could Be an Even Bigger Winner
02:30pm, Wednesday, 11'th Mar 2026
Eli Lilly is close to launching its own oral anti-obesity medicine, orforglipron. This new therapy could be better than oral Wegovy and allow Lilly to remain the weight-loss leader.
